Background and activities

Physician and specialist in oncology, both medical oncology and radiotherapy. Main research activity is focused on international, randomized, clinical intervention trials. The other main research area is the clinical role of liquid biopsies in lung cancer.

Other research topics include health related quality of life, older cancer patients, body composition and patient information.

ORCiD: 0000-0001-5744-1534

Education:

  • Medical doctor, University of Bergen, 1994

  • Specialist in Oncology, St. Olavs Hospital, Trondheim University Hospital, 2001

  • PhD in Clinical Medicine, NTNU, Norwegian University of Science and Technology, 2010

Current positions:

  • Full professor, Department of Clinical and Molecular Medicine, NTNU

  • Consultant in oncology, Cancer Clinic, St. Olav's Hospital, Trondheim university hospital (10% position)

  • Member of the Norwegian Board of Medical Experts for Patients with Life-Threatening Diseases (10% position)

  • Member of the board of the Norwegian Lung Cancer Study Group

Main research interests:

  • Lung cancer, especially small-cell lung cancer (SCLC), both medical treatment and radiotherapy.

  • Prognostic and predictive role of ctDNA-analyses in lung cancer patients.

  • Associations between comorbidity, frailty, functional status and treatment outcomes in cancer patients.

Main research projects:

  • Clinical role of ctDNA and miRNA analyses in lung cancer patients (https://www.ntnu.no/ikom/biopsi) funded by the Norwegian Cancer Society and The Liaison Committee for Education, Research and Innovation in Central Norway

  • Randomized trial comparing standard dose with high dose thoracic radiotherapy in limited stage small-cell lung cancer funded by the Norwegian Cancer Society and The Liaison Committee for Education, Research and Innovation in Central Norway

  • Randomized trial investigating whether adding atezolizumab after chemo-radiotherapy improves survival in limited stage small-cell lung cancer (https://www.ntnu.edu/ikom/achiles-trial) funded by the Norwegian Cancer Society and Roche

  • Randomized trial investigating whether adding thoracic radiotherapy to chemo-immunotherapy improves survival in extensive stage small-cell lung cancer funded by the Norwegian program for clinical research and AstraZeneca.

Supervision:

2 post-doctors, 16 PhD-students, and 15 medical students.

Institutional responsibilities:

  • Leader of the Cancer and palliative care research group (https://www.ntnu.no/ikom/kreftpalliasjon#/view/about) and Leader of the Translational cancer research unit (https://www.ntnu.no/ikom/transkreft) at the Department of clinical and molecular medicine, NTNU
  • Responsibility for treatment of lung cancer patients at the Cancer Clinic, St. Olav's Hospital.

Assignments:

  • Evaluation committee for the Cancer Fund at St. Olav's hospital (2010-).
  • Evaluation of Norwegian guidelines for diagnosis and treatment of cancer at the Norwegian Directorate of Health (2010-13).
  • Working group establishing the Norwegian Lung Cancer Quality Registry (2013-14).
  • Working group developing guidelines for diagnosis and treatment of CNS-tumors and lung cancer (2014-).
  • Comittee for the Clinical Research Program at the Norwegian Research Council (2014-16).
  • Working groups developing strategy for Personalized medicine in Norway (2015-18).
  • Ad hoc reviewer for Lancet, Lancet Oncology, Annals of Oncology, European Journal of Cancer, Journal of Thoracic Oncology, etc.

Memberships:

  • NLCG, Norwegian Lung Cancer Study Group (nlcg.no)
  • IASCL, International Association for the Study of Lung Cancer
  • ASCO, American Society of Clinical Oncology
  • ESMO, European Society for Medical Oncology

Scientific, academic and artistic work

A selection of recent journal publications, artistic productions, books, including book and report excerpts. See all publications in the database

Journal publications